AstraZeneca investors balk at Bristol Myers deal prospect

AstraZeneca investors punished the pharmaceutical firm yesterday over reports of merger talks with US rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.